The Chemours Company
NYSE:CCChemicals - Specialty
-$0.27 today
- Market cap
- $1.82B
- Beta
- 1.39
- P/E (TTM)
- -8.0
- EPS (TTM)
- -$2.73
- Dividend yield
- 1.61%
Volume 2.86M
Average 2.80M
CC Common Stock Repurchased
Cash spent buying back the company's own shares.
The Chemours CompanyNYSE: CC
Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026
Common stock repurchased outflow grows to $0
Q2 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0. Over 3 fiscal years it compounded at -87.4% a year.
Context
- Common stock repurchased amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
- Common stock repurchased increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Repurchased history
USD · from the cash flow
- Latest · FY2025
- (1M) USD
- Year-over-year change
- —
| Period | Period end | Common Stock Repurchased | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1M) | — |
| FY2024 | 2024-12-31 | 0 | +100.0% |
| FY2023 | 2023-12-31 | (69M) | +86.1% |
| FY2022 | 2022-12-31 | (495M) | -186.1% |
| FY2021 | 2021-12-31 | (173M) | — |
Common Stock Repurchased vs competitors
How CC compares with its peers on the latest reported figures
- CC's LTM Jun 2026 common stock repurchased of $0 is the 16th largest of the 19 companies compared; the peer median is $21.77M.
- Common stock repurchased amounts to 0.0% of revenue for CC, versus a peer median of 0.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $4.06B | -3.9% | -3.8% | 11.4% | |
| LTM Jun 2026 | $425M | -56.6% | +60.8% | 2.6% | |
| LTM Sep 2026 | $201M | +172.0% | -21.8% | 0.6% | |
| LTM Jun 2026 | $140M | -28.2% | +46.9% | 3.9% | |
| LTM Jun 2026 | $110M | +378.3% | — | 1.1% | |
| LTM Jun 2026 | $100M | +53.8% | -6.2% | 1.9% | |
| LTM Sep 2026 | $63M | -30.0% | -14.6% | 0.6% | |
| LTM Aug 2026 | $48.85M | -19.8% | +148.6% | 1.4% | |
| LTM Sep 2026 | $43.3M | +123.2% | -45.1% | 1.2% | |
| LTM Mar 2026 | $34.86M | +2260.3% | -30.0% | 4.3% | |
| LTM Sep 2026 | $8.69M | +15.8% | -28.8% | 0.6% | |
| LTM Mar 2026 | $6.58M | -85.7% | +79.3% | 0.4% | |
| LTM Sep 2026 | $5.03M | -83.3% | — | 0.2% | |
| LTM Jun 2026 | $1M | -99.6% | -20.6% | 0.1% | |
| LTM Jun 2026 | $295.88K | +101.1% | -6.5% | 0.0% | |
| LTM Jun 2026 | $0 | — | -87.4% | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding CC) | $21.77M | -3.9% | -6.5% | 0.6% | |
Competitors are the stored peer set for CC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 608M | 578M | (238M) | 86M | (386M) |
| Depreciation & Amortization | 317M | 291M | 307M | 301M | 340M |
| Deferred Income Tax | (77M) | 20M | (158M) | (27M) | 64M |
| Stock-Based Compensation | 34M | 27M | 19M | 15M | 21M |
| Change in Working Capital | 21M | (103M) | 620M | (1.05B) | 178M |
| Accounts Receivables | (225M) | 91M | 0 | (152M) | 106M |
| Inventory | (210M) | (294M) | 58M | (146M) | (106M) |
| Accounts Payables | 281M | 105M | (72M) | (9M) | (165M) |
| Other Working Capital | 175M | (5M) | 634M | (745M) | 343M |
| Other Non-Cash Items | (89M) | (58M) | 6M | 44M | 47M |
| Operating Cash Flow | 814M | 755M | 556M | (633M) | 264M |
| Capital Expenditures | (277M) | (307M) | (370M) | (360M) | (213M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 7M |
| Purchases of Investments | (12M) | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 509M | 23M | 141M | 7M | 0 |
| Investing Cash Flow | 220M | (284M) | (229M) | (353M) | (206M) |
| Debt Repayment | (208M) | (80M) | 393M | 95M | (61M) |
| Common Stock Issued | 0 | 0 | 0 | 9M | 0 |
| Common Stock Repurchased | (173M) | (495M) | (69M) | 0 | (1M) |
| Dividends Paid | (164M) | (154M) | (149M) | (148M) | (78M) |
| Other Financing Activities | (9M) | 43M | 16M | 8M | 14M |
| Financing Cash Flow | (554M) | (686M) | 172M | (36M) | (126M) |
| Effect of Forex Changes | (34M) | (32M) | 4M | (22M) | 27M |
| Net Change in Cash | 446M | (247M) | 503M | (1.04B) | (41M) |
| Free Cash Flow | 537M | 448M | 186M | (993M) | 51M |
The Chemours Company
NYSE:CC
Intrinsic Alpha fair value
Locked
Current Price
$12.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.